These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10332074)

  • 1. Cellular delivery of hammerhead ribozymes conjugated to a transferrin receptor antibody.
    Hudson AJ; Normand N; Ackroyd J; Akhtar S
    Int J Pharm; 1999 May; 182(1):49-58. PubMed ID: 10332074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular uptake properties of a 2'-amino/2'-O-methyl-modified chimeric hammerhead ribozyme targeted to the epidermal growth factor receptor mRNA.
    Fell PL; Hudson AJ; Reynolds MA; Usman N; Akhtar S
    Antisense Nucleic Acid Drug Dev; 1997 Aug; 7(4):319-26. PubMed ID: 9303183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipofectin-aided cell delivery of ribozyme targeted to human urokinase receptor mRNA.
    Karikó K; Megyeri K; Xiao Q; Barnathan ES
    FEBS Lett; 1994 Sep; 352(1):41-4. PubMed ID: 7925939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction between tumour necrosis factor alpha ribozyme and cellular proteins. Involvement in ribozyme stability and activity.
    Sioud M
    J Mol Biol; 1994 Oct; 242(5):619-29. PubMed ID: 7932719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery of a hammerhead ribozyme specifically down-regulates the production of fibrillin-1 by cultured dermal fibroblasts.
    Kilpatrick MW; Phylactou LA; Godfrey M; Wu CH; Wu GY; Tsipouras P
    Hum Mol Genet; 1996 Dec; 5(12):1939-44. PubMed ID: 8968747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of luciferase expression by synthetic hammerhead ribozymes and their cellular uptake.
    Bramlage B; Alefelder S; Marschall P; Eckstein F
    Nucleic Acids Res; 1999 Aug; 27(15):3159-67. PubMed ID: 10454613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hammerhead ribozymes targeted to the FBN1 mRNA can discriminate a single base mismatch between ribozyme and target.
    Phylactou LA; Tsipouras P; Kilpatrick MW
    Biochem Biophys Res Commun; 1998 Aug; 249(3):804-10. PubMed ID: 9731217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of a synthetic, chemically modified hammerhead ribozyme against the rat cytochrome P-450 3A2 mRNA after single intravenous injections.
    Desjardins JP; Sproat BS; Beijer B; Blaschke M; Dunkel M; Gerdes W; Ludwig J; Reither V; Rupp T; Iversen PL
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1419-27. PubMed ID: 8819529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribozymes as therapeutic tools for genetic disease.
    Phylactou LA; Kilpatrick MW; Wood MJ
    Hum Mol Genet; 1998; 7(10):1649-53. PubMed ID: 9735387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells.
    Hayashidani Y; Hiyama E; Murakami Y; Sueda T
    Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance.
    Beigelman L; McSwiggen JA; Draper KG; Gonzalez C; Jensen K; Karpeisky AM; Modak AS; Matulic-Adamic J; DiRenzo AB; Haeberli P
    J Biol Chem; 1995 Oct; 270(43):25702-8. PubMed ID: 7592749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural similarities between hammerhead ribozymes and the spliceosomal RNAs could be responsible for lack of ribozyme cleavage in yeast.
    Castanotto D; Li H; Chow W; Rossi JJ; Deshler JO
    Antisense Nucleic Acid Drug Dev; 1998 Feb; 8(1):1-13. PubMed ID: 9512091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and preparation of a multimeric self-cleaving hammerhead ribozyme.
    Ruiz J; Wu CH; Ito Y; Wu GY
    Biotechniques; 1997 Feb; 22(2):338-45. PubMed ID: 9043708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro selection of a purine nucleotide-specific hammerheadlike ribozyme.
    Vaish NK; Heaton PA; Fedorova O; Eckstein F
    Proc Natl Acad Sci U S A; 1998 Mar; 95(5):2158-62. PubMed ID: 9482855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The structure, function and application of the hammerhead ribozyme.
    Birikh KR; Heaton PA; Eckstein F
    Eur J Biochem; 1997 Apr; 245(1):1-16. PubMed ID: 9128718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of c-fms proto-oncogene in an ovarian carcinoma cell line by a hammerhead ribozyme.
    Yokoyama Y; Morishita S; Takahashi Y; Hashimoto M; Tamaya T
    Br J Cancer; 1997; 76(8):977-82. PubMed ID: 9376277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of variations in length of hammerhead ribozyme antisense arms upon the cleavage of longer RNA substrates.
    Sioud M
    Nucleic Acids Res; 1997 Jan; 25(2):333-8. PubMed ID: 9016562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 5'-end of hTERT mRNA is a good target for hammerhead ribozyme to suppress telomerase activity.
    Yokoyama Y; Takahashi Y; Shinohara A; Wan X; Takahashi S; Niwa K; Tamaya T
    Biochem Biophys Res Commun; 2000 Jun; 273(1):316-21. PubMed ID: 10873604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic hammerhead ribozymes as tools in gene expression.
    Lyngstadaas SP
    Crit Rev Oral Biol Med; 2001; 12(6):469-78. PubMed ID: 11806517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribozymes: from mechanistic studies to applications in vivo.
    Ohkawa J; Koguma T; Kohda T; Taira K
    J Biochem; 1995 Aug; 118(2):251-8. PubMed ID: 8543555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.